Web Analytics

3 Latest Announced Rounds

  • $3,700,000
    Seed

    1 Investors

    Technology, Information and Internet
    Apr 3rd, 2025
  • $5,000,000
    Unknown

    1 Investors

    Software Development
    Apr 3rd, 2025
  • $7,500,000
    Series A

    4 Investors

    Insurance
    Apr 3rd, 2025
$1,109.31M Raised in 40 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Reprieve Cardiovascular

start up
United States - Milford, Massachusetts
  • 21/02/2024
  • Series A
  • $42,000,000

Reprieve Cardiovascular, Inc. is developing innovative and groundbreaking therapies that aim to improve the lives of more than 25 million heart failure patients around the world. Reprieve is bringing intelligence to decongestion management to safely accelerate fluid removal for heart failure patients. In 2022, Reprieve initiated the FASTR Trial (pilot study) to compare decongestive therapy administered by the Reprieve Decongestion Management System to Optimal Diuretic Therapy in the treatment of patients diagnosed with acute decompensated heart failure.

Reprieve is a privately held medical device company, headquartered in Milford, Massachusetts, USA.


Related People

Mark PacynaFounder

Mark Pacyna United States - Minneapolis, Minnesota

N/A



Submit A Correction
Submit A Correction

Submit The Correction On the Page